Avadel Pharmaceuticals PLC (AVDL)
Official siteDRUG MANUFACTURERS - SPECIALTY & GENERIC
Last updated: Feb 12, 2026 at 4:00 PM ET
Avadel Pharmaceuticals PLC (AVDL) Financials: Revenue, Profit and Cash Flow
Avadel Pharmaceuticals reported revenue of $169.12M for the fiscal year ended Dec 31, 2024, up 504.8% from the year before. That year, net income was -$48.83M with a net margin of -28.9%, operating cash flow was -$46.91M and free cash flow was -$46.91M. The quarter ended Sep 30, 2025 had revenue of $77.47M and net income of $20.00K.
Revenue and Margins
The operating margin was -25.1% in the fiscal year ended Dec 2024. Over the 9 years to Dec 2024, revenue fell from $173.21M, a compound annual decline of 0.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $169.12M | +504.8% | 91.0% | -25.1% | -28.9% |
| Dec 2023 | $27.96M | N/A | 97.0% | -493.0% | -573.2% |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2020 | $22.33M | -62.3% | 74.3% | 26.0% | 31.5% |
| Dec 2019 | $59.22M | -42.7% | 79.5% | -40.7% | -56.1% |
| Dec 2018 | $103.27M | -40.2% | 83.0% | -101.6% | -92.3% |
| Dec 2017 | $172.74M | +15.0% | 90.6% | 51.1% | 38.9% |
| Dec 2016 | $150.25M | -13.3% | 91.2% | -3.3% | -27.5% |
| Dec 2015 | $173.21M | N/A | 93.7% | 41.2% | 23.5% |
Income Statement
In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $169.12M | $27.96M | $0 | $0 | $22.33M | $59.22M | $103.27M | $172.74M | $150.25M | $173.21M |
| Cost of revenue | $15.28M | $846.00K | $0 | $0 | $5.74M | $12.13M | $17.52M | $16.30M | $13.25M | $10.92M |
| Gross profit | $153.84M | $27.12M | $0 | $0 | $16.59M | $47.09M | $85.75M | $156.44M | $137.00M | $162.29M |
| Research and development | $15.20M | $13.26M | $20.70M | $17.10M | $20.44M | $32.92M | $39.33M | $34.22M | $34.61M | $25.61M |
| Operating income | -$42.40M | -$137.85M | -$98.56M | -$85.55M | $5.82M | -$24.11M | -$104.93M | $88.30M | -$4.96M | $71.45M |
| Net income | -$48.83M | -$160.28M | -$137.46M | -$77.33M | $7.03M | -$33.23M | -$95.30M | $67.25M | -$41.28M | $40.66M |
| EBITDA | -$35.57M | N/A | -$97.60M | -$82.39M | $9.60M | -$23.61M | -$95.14M | N/A | $5.73M | $115.54M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $77.47M | $68.13M | $52.51M | $50.41M | $50.02M | $41.50M | $27.18M | $19.45M | $7.01M | $1.50M | $0 | $0 |
| Gross profit | $80.47M | $61.76M | $46.93M | $45.60M | $43.87M | $38.72M | $25.66M | $18.76M | $6.90M | $1.46M | $0 | -$586.00K |
| Operating income | $1.94M | $8.88M | -$3.00M | -$3.30M | -$327.00K | -$12.74M | -$26.04M | -$24.90M | -$35.11M | -$49.54M | -$28.30M | -$23.22M |
| Net income | $20.00K | $9.66M | -$4.92M | -$5.04M | -$2.63M | -$13.82M | -$27.34M | -$28.79M | -$36.27M | -$64.43M | -$30.78M | -$27.45M |
Balance Sheet
As of Dec 2024, the balance sheet showed $51.37M in cash and equivalents and no debt.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $164.24M | $164.70M | $132.78M | $247.26M | $311.64M | $151.44M | $190.30M | $252.11M | $245.48M | $214.98M |
| Current assets | $134.21M | $134.20M | $100.84M | $192.49M | $263.45M | $82.38M | $124.85M | $123.95M | $181.19M | $166.31M |
| Cash and equivalents | $51.37M | $31.17M | $73.98M | $50.71M | $71.72M | $9.77M | $9.32M | $16.56M | $39.22M | $65.06M |
| Total liabilities | $90.39M | $76.96M | $153.93M | $169.02M | $149.37M | $180.63M | $187.52M | $167.54M | $203.41M | $147.11M |
| Short-term debt | $0 | $0 | $37.67M | $0 | $474.00K | $645.00K | $106.00K | $111.00K | $268.00K | $434.00K |
| Long-term debt | $0 | $0 | $91.61M | $142.40M | $128.21M | $121.69M | $115.73M | $156.00K | $547.00K | $684.00K |
| Shareholder equity | $73.85M | $87.74M | -$21.14M | $78.24M | $162.27M | -$29.20M | $2.78M | $84.56M | $42.07M | $67.86M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $199.45M | $187.16M | $167.95M | $164.24M | $158.25M | $157.52M | $167.90M | $164.70M | $203.10M | $200.98M | $140.74M | $204.13M |
| Total liabilities | $101.22M | $96.45M | $93.88M | $90.39M | $83.59M | $87.23M | $89.52M | $76.96M | $92.95M | $57.78M | $178.91M | $225.27M |
| Cash and equivalents | $79.81M | $63.40M | $56.37M | $51.37M | $28.58M | $28.85M | $35.79M | $31.17M | $51.81M | $49.98M | $83.39M | $73.98M |
| Shareholder equity | $98.22M | $90.71M | $74.07M | $73.85M | $74.66M | $70.29M | $78.38M | $87.74M | $110.15M | $143.19M | -$38.17M | -$21.14M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2024.
Annual
| Line item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$46.91M | -$128.51M | -$70.30M | -$77.31M | -$48.73M | -$38.33M | -$82.72M | $16.66M | $18.90M | $84.29M |
| Capital expenditures | $0 | $0 | $716.00K | $26.00K | $98.00K | $29.00K | $20.18M | $53.70M | $1.20M | $1.63M |
| Free cash flow | -$46.91M | -$128.51M | -$71.02M | -$77.34M | -$48.83M | -$38.35M | -$102.89M | -$37.04M | $17.70M | $82.66M |
| Share repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $27.64M | $22.36M | $0 | $0 |
| Investing cash flow | $51.78M | -$50.09M | $79.70M | $56.93M | -$69.72M | $38.72M | -$36.98M | -$15.70M | -$36.63M | -$31.73M |
| Financing cash flow | $15.97M | $135.34M | $14.54M | $263.00K | $179.68M | -$27.00K | $112.66M | -$23.32M | -$7.95M | -$23.75M |
Quarterly
| Line item | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $23.26M | $12.70M | -$8.23M | $7.87M | -$6.89M | -$18.19M | -$29.70M | -$28.03M | -$38.23M | -$32.02M | -$30.23M | -$15.37M |
| Capital expenditures | $10.76K | $181.00K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $716.00K |
| Free cash flow | $23.25M | $12.52M | -$8.23M | $7.87M | -$6.89M | -$18.19M | -$29.70M | -$28.03M | -$38.23M | -$32.02M | -$30.23M | -$16.08M |
Frequently Asked Questions About AVDL
What is Avadel Pharmaceuticals' annual revenue?
Avadel Pharmaceuticals reported revenue of $169.12M for the fiscal year ended Dec 31, 2024.
How fast is Avadel Pharmaceuticals' revenue growing?
Revenue was up 504.8% for the fiscal year ended Dec 31, 2024 compared with the year before.
Is Avadel Pharmaceuticals profitable?
No. Avadel Pharmaceuticals reported net income of -$48.83M for the fiscal year ended Dec 31, 2024, with a net margin of -28.9%.
How much free cash flow does AVDL generate?
For the fiscal year ended Dec 31, 2024, operating cash flow of -$46.91M minus capital expenditures of $0 produced free cash flow of -$46.91M.
How much debt does Avadel Pharmaceuticals have?
The balance sheet dated Dec 31, 2024 reported long-term debt of $0, short-term debt of $0 and cash and equivalents of $51.37M.
AVDL pages: Overview, Financials